Key result
RRV is 100% infective and immunogenic in infants without transmission but linked to early fever.
Why the study?
Does rhesus rotavirus vaccine (RRV) MMU 18006 induce immunity safely without transmission in infants?
Population
27 infants ages 5 to 20 months
Comparison
Rhesus rotavirus vaccine MMU 18006, 10^5… vs Placebo
Design
RCT, randomized, double-blind
Authors
Loading...
Supports infant rotavirus immunization without transmission risk; confirms high immunogenicity with mild fever in RCT.
RCT (n=27)
double-blind
randomized
Does rhesus rotavirus vaccine (RRV) MMU 18006 induce immunity safely without transmission in infants?
The rhesus rotavirus vaccine MMU 18006 is highly immunogenic and infective in infants without evidence of transmission, though it may cause mild fever.
Losonsky et al. (1986) reported an RCT. rhesus rotavirus vaccine (RRV) MMU 18006 vs. placebo was evaluated on infectivity and immunogenicity. Rhesus rotavirus vaccine (MMU 18006) was 100% infective and immunogenic in vaccinated infants, with no evidence of transmissibility but an association with fever on Days 3 and 4.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: